News

FDA detects a new counterfeit bevacizumab


 

An unapproved medicine is being distributed as bevacizumab by Medical Device King, a U.S.-based company also known as Pharmalogical and Taranis Medical, the Food and Drug Administration has announced.

Tests have confirmed that there is no active ingredient in at least one batch of the counterfeit version of Roche’s Altuzan 400 mg/16 mL, an injectable version of bevacizumab that is not approved in the United States.

Avastin (Genentech) is the only FDA-approved version of bevacizumab for sale in the United States.

The FDA is advising practices to stop using any medical products that may have been obtained from Medical Device King, Pharmalogical, and Taranis Medical and to contact FDA’s Office of Criminal Investigations to arrange for the collection of these products.

To report suspect products obtained from Medical Device King, Pharmalogical, Taranis Medical, or other questionable sources, contact the FDA’s Office of Criminal Investigations at 800-551-3989, www.accessdata.fda.gov/scripts/email/oc/oci/contact.cfm, or via e-mail to DrugSupplyChainIntegrity@fda.hhs.gov.

m.dales@elsevier.com

Recommended Reading

FDA approves bevacizumab for second-line combinations
MDedge Internal Medicine
Lenalidomide branches out to lymphoma therapy
MDedge Internal Medicine
Transplants don't boost overall survival in high-risk DLBCL
MDedge Internal Medicine
In Europe, melanoma is rising in men over 60
MDedge Internal Medicine
New tool predicts late recurrence in breast cancer
MDedge Internal Medicine
Second-line agent for gastroesophageal adenocarcinoma ups survival
MDedge Internal Medicine
Prostatectomy vs. radiotherapy: 15-year functional outcomes are same
MDedge Internal Medicine
Poll: Public doesn't see cancer as a death sentence
MDedge Internal Medicine
Statins may reduce mortality in hepatocellular cancer
MDedge Internal Medicine
Obesity, diabetes fuel liver disease epidemic
MDedge Internal Medicine